DBVT Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
DBV Technologies S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.47 |
| 52 Week High | €2.14 |
| 52 Week Low | €0.44 |
| Beta | 0.86 |
| 11 Month Change | -45.87% |
| 3 Month Change | -47.89% |
| 1 Year Change | -70.69% |
| 33 Year Change | -92.18% |
| 5 Year Change | -96.99% |
| Change since IPO | -99.18% |
Recent News & Updates
Recent updates
FDA puts partial clinical hold on a DBT Technologies peanut allergy patch phase 3 trial
Sep 21DBV Technologies GAAP EPS of -$0.35 misses by $0.03, revenue of $1.53M beats by $0.29M
Aug 01DBV Technologies: Good Data, Plenty Of Cash And Regulatory Uncertainty
Jul 07DBV Technologies reports change in U.S. reporting status, cuts headcount
Jan 07DBV Technologies CSO Hugh Sampson to step down from role
Nov 24DBV Technologies shares rockets 85% as EMA approves Viaskin Peanut application
Nov 02Shareholder Returns
| DBVT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -20.5% | 2.5% | 2.2% |
| 1Y | -70.7% | 16.1% | 31.6% |
Return vs Industry: DBVT underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: DBVT underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| DBVT volatility | |
|---|---|
| DBVT Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DBVT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DBVT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 108 | Daniel Tassé | www.dbv-technologies.com |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
DBV Technologies S.A. Fundamentals Summary
| DBVT fundamental statistics | |
|---|---|
| Market cap | US$54.37m |
| Earnings (TTM) | -US$102.09m |
| Revenue (TTM) | US$12.52m |
4.3x
P/S Ratio-0.5x
P/E RatioIs DBVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DBVT income statement (TTM) | |
|---|---|
| Revenue | US$12.52m |
| Cost of Revenue | US$0 |
| Gross Profit | US$12.52m |
| Other Expenses | US$114.60m |
| Earnings | -US$102.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.06 |
| Gross Margin | 100.00% |
| Net Profit Margin | -815.73% |
| Debt/Equity Ratio | 0% |
How did DBVT perform over the long term?
See historical performance and comparison